Search results for "adolescent"

showing 10 items of 6718 documents

Total Hemi-overgrowth in Pigmentary Mosaicism of the (Hypomelanosis of) Ito Type: Eight Case Reports.

2016

Abstract Pigmentary mosaicism of the (hypomelanosis of) Ito type is an umbrella term, which includes phenotypes characterized by mosaic hypopigmentation in the form of streaks, whorls, patchy, or more bizarre skin configurations (running along the lines of Blaschko): these cutaneous patterns can manifest as an isolated skin disorder (pigmentary mosaicism of the Ito type) or as a complex malformation syndrome in association with extracutaneous anomalies (most often of the musculoskeletal and/or nervous systems) (hypomelanosis of Ito). Affected individuals are anecdotally reported to have also partial or total body hemi-overgrowth (HOG), which often causes moderate to severe complications. We…

0301 basic medicineModerate to severeAdultMalePathologymedicine.medical_specialtyAdolescentDevelopmental DisabilitiesContext (language use)030105 genetics & heredity03 medical and health sciences0302 clinical medicinemedicineHumansAbnormalities MultipleClinical Case ReportClinical phenotypeChildKyphoscoliosisPigmentation disorderHypopigmentationChromosome AberrationsHypopigmentationbusiness.industryMosaicismFollow up studiesTotal bodyGeneral Medicinemedicine.diseaseMagnetic Resonance Imaging6200Musculoskeletal Abnormalitieshypomelanosis Ito type Pigmentary mosaicism mosaic hypopigmentation childrenPhenotypeItalyChild PreschoolKaryotypingFemalemedicine.symptombusinessPigmentation Disorders030217 neurology & neurosurgeryResearch ArticleFollow-Up StudiesMedicine
researchProduct

Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing : a split-mouth randomised clinical trial

2018

Background Since the discovery of adult mesenchymal stem cells extensive research has been conducted to determine their mechanisms of differentiation and effectiveness in cell therapy and regenerative medicine. Material and Methods To assess the efficacy of autologous dental pulp mesenchymal stem cells delivered in a collagen matrix for post-extraction socket healing, a single-centre, double-blind, randomised, split-mouth, controlled clinical trial was performed. Both impacted mandibular third molars were extracted from 32 patients. Dental pulp was collected and dissociated; the resulting cell suspension, obtained by centrifugation, was incorporated into a resorbable collagen matrix and imp…

0301 basic medicineMolarAdultMaleAdolescentDentistryBone healingMesenchymal Stem Cell TransplantationBone resorptionMandibular second molar03 medical and health sciencesYoung AdultDouble-Blind MethodHounsfield scaleMedicineHumansTooth SocketAutograftsGeneral DentistryDental PulpPostoperative CareWound Healingbusiness.industryResearchMesenchymal stem cellInterdental consonant:CIENCIAS MÉDICAS [UNESCO]030104 developmental biologyOtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryFemaleMolar ThirdOral SurgeryWound healingbusiness
researchProduct

Association between DNA methylation and ADHD symptoms from birth to school age: a prospective meta-analysis

2020

Funder: Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada); doi: https://doi.org/10.13039/501100000024

0301 basic medicineOncology3124 Neurology and psychiatryEpigenesis GeneticACTIVATION0302 clinical medicine3123 Gynaecology and paediatricsPregnancyProspective StudiesProspective cohort studyChildRISK0303 health sciencesSchoolsATTENTION-DEFICIT/HYPERACTIVITY DISORDERMethylation3. Good healthPsychiatry and Mental healthMeta-analysisChild PreschoolDNA methylation/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingBiomarker (medicine)FemalePACKAGEmedicine.medical_specialtyAdolescent515 PsychologyArticlelcsh:RC321-571Cellular and Molecular Neuroscience03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicinemedicineGeneticsAttention deficit hyperactivity disorderHumansEpigeneticslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological Psychiatry030304 developmental biologyGenetic associationPregnancybusiness.industryInfant NewbornPERFORMANCEDNA Methylationmedicine.diseaseGENE030104 developmental biologyAttention Deficit Disorder with HyperactivityCOHORT PROFILEEtiologybusinessPsychiatric disorders030217 neurology & neurosurgery
researchProduct

Improving the Management of Patients with Hearing Loss by the Implementation of an NGS Panel in Clinical Practice

2020

A cohort of 128 patients from 118 families diagnosed with non-syndromic or syndromic hearing loss (HL) underwent an exhaustive clinical evaluation. Molecular analysis was performed using targeted next-generation sequencing (NGS) with a custom panel that included 59 genes associated with non-syndromic HL or syndromic HL. Variants were prioritized according to the minimum allele frequency and classified according to the American College of Medical Genetics and Genomics guidelines. Variant(s) responsible for the disease were detected in a 40% of families including autosomal recessive (AR), autosomal dominant (AD) and X-linked patterns of inheritance. We identified pathogenic or likely pathogen…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyAdolescentlcsh:QH426-470Hearing lossHearing Loss Sensorineuralclinical evaluationPopulationGenomicsDiseaseDeafnessArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansgeneticsmolecular analysiseducationChildAllele frequencyGenetics (clinical)hearing losseducation.field_of_studybusiness.industryInfant NewbornHigh-Throughput Nucleotide SequencingInfantMiddle Agedmedicine.diseaselcsh:Genetics030104 developmental biologyChild PreschoolCohortMedical geneticsSensorineural hearing lossFemalenext-generation sequencingmedicine.symptombusiness030217 neurology & neurosurgeryGenes
researchProduct

High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial

2018

Background: Patients with extremity and trunk wall soft tissue sarcoma (STS) with high malignancy grade and size >5 cm are at high-risk of death. This risk varies depending also on other patient and tumour features, including histologic subtype. This study investigated whether a prognostic nomogram can improve risk assessment of these patients. Methods: Data from high-risk STS patients enrolled in a randomised controlled trial investigating different perioperative chemotherapy regimens were analysed. Ten-year probability of overall survival (OS) and incidence of distant metastasis (DM) were computed using the prognostic nomogram Sarculator (pr-OS and inc-DM, respectively). Tumour response a…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyCancer ResearchAdolescentTumour responsePerioperative Care03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOutcome Assessment Health Caremedicinemedia_common.cataloged_instanceHumansChemotherapyEuropean unionSurvival ratemedia_commonAgedSoft tissue sarcomabusiness.industryChemotherapy; Choi criteria; Neoadjuvant; Prognosis; Soft tissue sarcoma; Tumour response; Oncology; Cancer ResearchSoft tissue sarcomaIncidence (epidemiology)SarcomaNomogramMiddle Agedmedicine.diseasePrognosisClinical trialSurvival RateNomograms030104 developmental biologyChoi criteriaOncology030220 oncology & carcinogenesisFemaleSarcomaNeoadjuvantRisk assessmentbusinessFollow-Up Studies
researchProduct

Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients

2017

The immunomodulatory role of human leukocyte antigen (HLA)-E in hematopoietic stem cell transplantation (HSCT) has not been extensively investigated. To this end, we genotyped 509 10/10 HLA unrelated transplant pairs for HLA-E, in order to study the effect of HLA-E as a natural killer (NK)-alloreactivity mediator on HSCT outcome in an acute leukemia (AL) setting. Overall survival (OS), disease free survival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were set as endpoints. Analysis of our data revealed a significant correlation between HLA-E mismatch and improved HSCT outcome, as shown by both univariate (53% vs. 38%, P=0.002, 5-year OS) and multivariate (hazard ratio (HR)…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentGenotypemedicine.medical_treatment610Hematopoietic stem cell transplantationHuman leukocyte antigen600 Technik Medizin angewandte Wissenschaften::610 Medizin und GesundheitArticle03 medical and health sciencesYoung Adult0302 clinical medicineCell Therapy & ImmunotherapyInternal medicineMedicineHumansTransplantation Homologousddc:610Potassium Channels Inwardly RectifyingSurvival analysisAllelesAgedBone Marrow TransplantationAcute leukemiabusiness.industryDonor selectionHistocompatibility TestingHazard ratioHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisTransplantationLeukemiaLeukemia Myeloid Acute030104 developmental biologyTreatment OutcomeImmunologyFemalebusiness030215 immunology
researchProduct

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.

2017

Several novel single nucleotide polymorphisms (SNPs) involved in cytarabine cytotoxicity and related to clinical outcomes have been reported recently in a series of 232 pediatric patients with acute myeloid leukemia (AML). We report the first adult AML cohort in which the influence of these SNPs in cytarabine efficacy and toxicity was analyzed. Six of polymorphisms with clinical significance in the previous study [rs12036333, rs10758713, rs9883101, rs6550826, IRX2: rs2897047, mutated in colorectal cancers (MCC): rs7729269] were analyzed in a cohort of 225 adult patients at initial diagnosis of AML treated with an induction scheme of idarubicin plus cytarabine. The variant alleles of rs12036…

0301 basic medicineOncologyAdultmedicine.medical_specialtyAdolescentPopulationSingle-nucleotide polymorphismKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineGeneticsmedicineIdarubicinHumansGeneral Pharmacology Toxicology and PharmaceuticseducationProspective cohort studyMolecular BiologyGenetics (clinical)Agededucation.field_of_studybusiness.industryCytarabineInduction chemotherapyMyeloid leukemiaInduction ChemotherapyMiddle AgedMinor allele frequencyLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisCytarabineMolecular Medicinebusinessmedicine.drugPharmacogenetics and genomics
researchProduct

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemothera…

2016

Abstract Background The recommendation for adjuvant dose-dense chemotherapy in high risk primary breast cancer is heterogeneous among guidelines. Understanding the impact on QoL is thereby a crucial factor, especially if the benefit is potentially low. This study aims to assess QoL as a secondary outcome in the prospective randomized multi-center ADEBAR trial. Methods QoL was assessed at baseline (t1), before cycle 4 FEC and cycle 5 EC-DOC (t2), 4 weeks after chemotherapy (t3) and 6 weeks after radiation (t4) using the European Organization for Research and Treatment for Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) and the Breast Cancer-Specific Module (QLQ-BR23). Results 130…

0301 basic medicineOncologyAdultmedicine.medical_specialtyTime FactorsAdolescentNauseamedicine.medical_treatmentBreast NeoplasmsDocetaxelDrug Administration Schedule03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideAgedEpirubicinChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseasehumanitiesSurgery030104 developmental biologyTreatment OutcomeDocetaxelFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisQuality of LifeSurgeryFemaleTaxoidsFluorouracilmedicine.symptombusinessmedicine.drugEpirubicinBreast (Edinburgh, Scotland)
researchProduct

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the Europe…

2020

Background Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in the FDA drug label and a pharmacogenetic guideline. The aim of this cross-sectional cohort study was to confirm the genetic associations in a large pan-European population and to evaluate the diagnostic accuracy of the genetic…

0301 basic medicineOncologyMaleCancer ResearchCandidate genePharmacogenomic VariantsCancer survivorsCHILDRENAnti-neoplastic drugsVARIANTSOCT2Carboplatin0302 clinical medicineHearingRisk FactorsNeoplasmsTPMTHearing / drug effectsProspective StudiesAge of OnsetChild610 Medicine & healthPREDICTORSmedia_commonHearing Loss Sensorineural / physiopathologyeducation.field_of_studyddc:618Thiopurine methyltransferasebiologycarboplatin [Cisplatin]Neoplasms / drug therapyOrganic Cation Transporter 2EuropeOncologyCisplatin: carboplatinCisplatin / adverse effects030220 oncology & carcinogenesisChild PreschoolOrganic Cation Transporter 2 / geneticsFemaleSENSITIVITYChildhood cancer360 Social problems & social servicesCohort studyDrug-induced ototoxicitymedicine.medical_specialtyINDUCED HEARING-LOSSAdolescentMulticenter cohort studyHearing Loss SensorineuralPopulationAdverse drug reactionAntineoplastic AgentsPolymorphism Single NucleotideRisk AssessmentHearing Loss Sensorineural / chemically inducedCarboplatin / adverse effects03 medical and health sciencesACYP2OtotoxicitySDG 3 - Good Health and Well-beingInternal medicinemedicineGenetic predispositionmedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseCISPLATIN-INDUCED OTOTOXICITYEuropean unioneducationGenetic Association StudiesGenetic associationRetrospective Studiesbusiness.industryAntineoplastic Agents / adverse effectsInfant NewbornInfantOdds ratioGuidelinemedicine.diseaseOtotoxicityCOMTPharmacogenomic Testing030104 developmental biologyCross-Sectional StudiesPharmacogeneticsbiology.proteinGenetic markersHearing Loss Sensorineural / geneticsCisplatinbusinessPharmacogenetics
researchProduct

Ectopic myoglobin expression is associated with a favourable outcome in head and neck squamous cell carcinoma patients

2016

BACKGROUND/AIM: Ectopic myoglobin (MB) expression, mediated by alternative and hypoxia-inducible transcription, has recently been demonstrated in several epithelial tumours. This study aimed to examine the expression of MB in hormone-independent head and neck squamous cell carcinomas (HNSCCs). PATIENTS AND METHODS: Using imunohistochemistry, ectopic MB expression was analyzed on tissue microarrays (TMAs) of 524 patients with localized and locally advanced primary and recurrent HNSCC who had undergone surgical treatment with curative intent. Associations of MB expression with survival and clinicopathological parameters were analyzed. RESULTS: MB expression was found in 45.8% of HNSCC patient…

0301 basic medicineOncologyMaleCancer ResearchPathologyCellMedizinchemistry.chemical_compound0302 clinical medicineMedicine1306 Cancer ResearchHead and neckSurgical treatmentChildTissue microarrayMyoglobinHazard ratioGeneral MedicineMiddle Aged10081 Institute of Veterinary Physiologymedicine.anatomical_structureTreatment OutcomeOncologyMyoglobinHead and Neck Neoplasms030220 oncology & carcinogenesisChild PreschoolCarcinoma Squamous CellFemale2730 OncologyAdultmedicine.medical_specialtyHPVAdolescenthead and neck squamous cell carcinoma03 medical and health sciencesYoung AdultInternal medicineHumansbusiness.industryInfant NewbornInfantmedicine.diseaseHead and neck squamous-cell carcinomaConfidence interval030104 developmental biologychemistry570 Life sciences; biologyprognosisbusiness
researchProduct